Rhythm's EMANATE Trial Misses Endpoint But Shows BMI Reductions

Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial of setmelanotide, an MC4R agonist for rare, genetically driven forms of obesity. The release provided no detailed efficacy, safety metrics or regulatory timing, leaving clinical and commercial implications unclear until full data are disclosed.

Analysis

Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial of setmelanotide, an MC4R agonist for rare, genetically driven forms of obesity. The release provided no detailed efficacy, safety metrics or regulatory timing, leaving clinical and commercial implications unclear until full data are disclosed.